Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03640312 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT03640312 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 62 participants.
The verdict
NCT03640312, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
To investigate, in a double-blind randomized controlled trial, whether initiating treatment with ultra-low-dose quadruple-combination therapy ("LDQT") will lower office blood pressure more effectively, and with fewer side effects, compared to initiating standard dose monotherapy as per current guidelines in patients with hypertension. Primary hypothesis: A combination pill comprising four types of blood pressure lowering medications, each at one-quarter standard doses, will lower office blood pressure more effectively than initiating patients with standard dose monotherapy as per contemporary clinical practice guideline recommendations.
Interventions
- DRUG Candesartan
- DRUG QUARTET LDQT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-08-30 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03640312
The ClinicalTrials.gov registry entry for NCT03640312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Candesartan is the first listed.
NCT03640312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03640312 about?
NCT03640312 is a clinical study titled "Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension". To investigate, in a double-blind randomized controlled trial, whether initiating treatment with ultra-low-dose quadruple-combination therapy ("LDQT") will lower office blood pressure more effectively, and with fewer side effects, compared to initiating standard dose monotherapy as per current guide...
What is the current status of trial NCT03640312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2019-08-30. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT03640312?
The interventions under investigation include: Candesartan (DRUG), QUARTET LDQT (DRUG).
Who is sponsoring clinical trial NCT03640312?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.